Biotie Therapies - Annual Financial Report

Biotie's Financial Statement Report and Corporate Governance Statement 2015 published

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE   March 22, 2016 at 10 a.m.

Biotie's Financial Statement Report and Corporate Governance Statement 2015
published

Biotie Therapies Corp.'s (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the
"Company") Financial Statement Report for the financial period ended 31 December
2015 and Corporate Governance Statement 2015 have been published.

The documents are attached in pdf format to this release. Both documents are
also available on the Company's website www.biotie.com in English and Finnish
language.

In addition, Biotie expects to file its 2015 annual report on Form 20-F with the
U.S. Securities and Exchange Commission (the "SEC") later today. The Form 20-F
will be available on Biotie's website after it is filed with the SEC.

Turku, March 22, 2016

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
Nasdaq Helsinki Ltd
Main Media
www.biotie.com

About Biotie

Biotie is a biopharmaceutical company focused on products for neurodegenerative
and psychiatric disorders. Biotie's development has delivered Selincro
(nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is in Phase 3 development, and two additional compounds which are
in Phase 2 development for cognitive disorders including Parkinson's disease
dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of
the liver.

Biotie's shares are listed on NASDAQ Helsinki (BTH1V) and ADS on Nasdaq Stock
Market LLC (BITI).


[HUG#1996641]

Viðhengi:

Biotie_Corporate Governance Statement 2015.pdf

Biotie_Financial Statements 2015.pdf